Complete Genomics, Inc.  

(Public, NASDAQ:GNOM)   Watch this stock  
Find more results for GNOM
Mar 18 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 1.57 - 3.50
Open     -
Vol / Avg. 0.00/133,057.00
Mkt cap 108.29M
P/E     -
Div/yield     -
EPS -2.35
Shares     -
Beta     -
Inst. own     -

Key stats and ratios

Q3 (Sep '12) 2011
Net profit margin -247.24% -374.01%
Operating margin -237.99% -358.22%
EBITD margin - -297.66%
Return on average assets -81.99% -62.00%
Return on average equity -178.56% -92.61%
Employees 270 -
CDP Score - -


2071 Stierlin Court
United States - Map
+1-650-9432800 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Complete Genomics, Inc. is a life sciences company that has developed and commercialized a deoxyribonucleic acid (DNA) sequencing platform. Its complete genomics analysis platform (CGA) Platform, combines its human genome sequencing technology with its advanced informatics and data management software and its end-to-end, outsourced service model to provide its customers with data that is ready to be used for genome-based research. Its genome sequencing center combines a high-throughput sample preparation facility, a collection of its high-throughput sequencing instruments and a large- scale data center. Its customers include some of the global academic and government research centers and biopharmaceutical companies. Effective March 18, 2013, BGI-Shenzhen announced that through its wholly-owned subsidiary, Beta Acquisition Corporation, it has completed the acquisition of the Company.